

Product Data Sheet

Product Name: Racotumomab

Cat. No.: GC72344

Chemical Properties

Cas. No. 946832-34-4

Formula

M.Wt

Solubility

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Racotumomab

Background

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotypic monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death^[4].

Racotumomab (50 µg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model^[2].

Racotumomab (50 µg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft^[3].

Racotumomab (50-200 µg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft^[3].

References:

- [1]. Vázquez AM, et al. Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. *Front Oncol.* 2012 Oct 23;2:150.
- [2]. Gajdosik Z. Racotumomab - a novel anti-idiotypic monoclonal antibody vaccine for the treatment of cancer. *Drugs Today (Barc).* 2014 Apr;50(4):301-7.
- [3]. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. *Front Oncol.* 2012 Nov 8;2:160.
- [4]. Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. *Vaccines (Basel).* 2022 Feb 4;10(2):240.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA